Matthew T. Wiley's Net Worth
-$68.9 Thousand
Who is Matthew T. Wiley?
Matthew T. Wiley does not have any significant net worth to report based on the numbers we have. This is based on reported shares across multiple companies, which include Foamix Pharmaceuticals Ltd., BioXcel Therapeutics, Inc., and Menlo Therapeutics Inc..
SEC CIK
Matthew T. Wiley's CIK is 0001759703
Past Insider Trading and Trends
2020 was Matthew T. Wiley's most active year for acquiring shares with 3 total transactions. Matthew T. Wiley's most active month to acquire stocks was the month of February. 2020 was Matthew T. Wiley's most active year for disposing of shares, totalling 4 transactions. Matthew T. Wiley's most active month to dispose stocks was the month of February. 2019 saw Matthew T. Wiley paying a total of $71,783.28 for 23,282 shares, this is the most they've acquired in one year. In 2019 Matthew T. Wiley cashed out on 2,500 shares for a total of $8,200.00, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Foamix Pharmaceuticals Ltd. No price found
Chief Commercial Officer
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -100.00% | -114.07K |
—
|
—
|
0
|
Mar 9
| |||
Form 4
| +1.78% | 1.99K |
$2.68 | $5,336.26 | 114.07K |
Mar 2
| |||
Form 4
| +58.35% | 41.3K |
—
|
—
| 112.08K |
Feb 24
| |||
Form 4
| -3.41% | -2.50K |
$3.28 | -$8,200.00 | 70.78K |
Dec 31
| |||
Form 4
| +15.51% | 9.84K |
$2.16 | $21,248.88 | 73.28K |
Nov 29
| |||
Form 4
| +26.88% | 13.44K |
$3.76 | $50,534.40 | 63.44K |
Mar 5
| |||
Form 4
|
∞
| 50K |
—
|
—
| 50K |
Dec 3
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
BioXcel Therapeutics, Inc. (BTAI) Snapshot price: $3.77
Chief Commercial Officer
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| +16.91% | 506 |
$1.26 | -$308.10 | 3.5K |
Scheduled
|
Jun 15 - Jun 17
| ||
Form 4
| +49.80% | 1.99K |
$2.64 | -$2,656.18 | 5.99K |
Scheduled
|
Mar 15 - Apr 4
| ||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Mar 15
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 17
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Menlo Therapeutics Inc. (VYNE) Snapshot price: $2.105
Chief Commercial Officer
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||